NKGen Biotech to Present Troculeucel at Cell and Gene Therapy Forum
News related to:NKGen Biotech, Inc · 1 min read
SANTA ANA, Calif., Sept. 15, 2026 /CourierPR/ -- NKGen Biotech, Inc., a clinical-stage biotechnology company based in Santa Ana, California, will present its lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum in Guangzhou, China, on September 22-23, 2026. The presentation, led by NKGen’s Chairman and CEO, Dr. Paul Y. Song, will focus on the application of troculeucel in neurodegenerative diseases.
Dr. Song’s presentation will delve into the proposed mechanism of action of troculeucel, highlighting changes observed in neuroinflammatory and protein biomarkers in cerebrospinal fluid. The presentation will also explore the clinical experience of patients with Alzheimer’s disease, as well as potential applications in Parkinson’s disease and frontotemporal dementia.
Troculeucel is a novel cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. Developed by NKGen, troculeucel is being evaluated for the treatment of neurodegenerative disorders and a broad range of cancers. The International Nonproprietary Name (INN) for SNK01, troculeucel was recently assigned by the World Health Organization, marking a significant step in the company’s journey toward commercialization.
The presentation will be available on the company’s website under the Scientific Publications section following the event. Previously disclosed scientific data on troculeucel for neurodegenerative disease can be accessed on the same page. For the latest updates on the company’s clinical trials and regulatory announcements, interested parties can visit the company’s News page.
NKGen Biotech, Inc. continues to advance its innovative autologous and allogeneic NK cell therapeutics, with a particular focus on addressing unmet needs in neurodegenerative diseases. The company’s commitment to bringing troculeucel to market underscores its dedication to improving patient outcomes through cutting-edge biotechnology.